Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

EBioMedicine. 2020 Nov:61:103046. doi: 10.1016/j.ebiom.2020.103046. Epub 2020 Oct 7.

Authors

Isabelle Ray-Coquard¹, Hélène Vanacker², Olivia Le Saux³, Olivier Tredan⁴

Affiliations

¹ Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France; University Claude Bernard Lyon 1, Lyon, France. Electronic address: [email protected].
² Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France; University Claude Bernard Lyon 1, Lyon, France.
³ Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France; Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052, CNRS 5286, Centre Léon-Bérard, Lyon, France.
⁴ Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Carcinoma, Ovarian Epithelial / drug therapy*
Carcinoma, Ovarian Epithelial / etiology
Carcinoma, Ovarian Epithelial / metabolism
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Molecular Targeted Therapy
Mutation
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / genetics
Ovarian Neoplasms / metabolism
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Poly(ADP-ribose) Polymerase Inhibitors